Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 323Fallopian Tube Neoplasms 159Carcinoma, Ovarian Epithelial 114Endometrial Neoplasms 77Uterine Cervical Neoplasms 72Neoplasms 28Carcinoma, Non-Small-Cell Lung 24Breast Neoplasms 23Brenner Tumor 21Recurrence 19Testicular Neoplasms 17Peritoneal Neoplasms 17Stomach Neoplasms 14Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Urinary Bladder Neoplasms 10Testicular Germ Cell Tumor 10Sarcoma 10Pancreatic Neoplasms 10Lung Neoplasms 10Colorectal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Parkinson Disease 4, Autosomal Dominant Lewy Body 9Teratoma 8Ovarian Germ Cell Cancer 8Neuroectodermal Tumors, Primitive, Peripheral 8Central Nervous System Neoplasms 8Uterine Neoplasms 7Small Cell Lung Carcinoma 7Melanoma 7

Interventions

enzalutamide 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Endometrial Endometrioid Adenocarcinoma × Carboplatin × Gynecologic × Clear all
NCT02684227 2025-03-19

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
50 enrolled 14 charts
Gynecologic

Recurrent Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡